SUPN
Supernus Pharmaceuticals, Inc.
Price Chart
Latest Quote
$44.38
+0.80 (+1.84%)
Current Price
| Previous Close | $43.58 |
| Open | $44.07 |
| Day High | $44.58 |
| Day Low | $43.62 |
| Volume | 902,835 |
Stock Information
| Shares Outstanding | 58.04M |
| Total Debt | $40.90M |
| Cash Equivalents | $384.24M |
| Revenue | $776.83M |
| Net Income | $-29.02M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $2.58B |
| EPS (TTM) | $-0.51 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.19B |
| Sales | $776.83M |
| Income | $-29.02M |
| Book/sh | $18.48 |
| Cash/sh | $6.62 |
| Employees | 778 |
Financial Ratios
| Quick Ratio | 1.51 |
| Current Ratio | 1.96 |
| Debt/Eq | 3.80 |
Returns & Margins
| ROA | 1.11% |
| ROE | -2.75% |
| Gross Margin | 74.13% |
| Operating Margin | -3.58% |
| Profit Margin | -3.74% |
Ownership
| Insider Ownership | 4.46% |
| Institutional Ownership | 103.90% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.22 |
| P/S | 3.32 |
| P/B | 2.40 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $62.83 |
Technical Indicators
| SMA20 | $45.40 |
| SMA50 | $48.07 |
| SMA200 | $48.99 |
| RSI | 38.89 |
| ATR | 1.4936 |
| Shares Float | 52.12M |
| Short Float | 11.47% |
| Short Ratio | 7.21 |
| Volatility | 0.54 |
| Rel Volume | 1.75 |
Performance History
| Week | -2.57% |
| Month | -6.80% |
| Quarter | -9.13% |
| 6 Months | -8.15% |
| YTD | -10.29% |
| Year | +37.27% |
| 3 Years | +31.03% |
| 5 Years | +42.24% |
| 10 Years | +142.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $nan | 902,835 |
| 2026-06-17 | $43.58 | 563,000 |
| 2026-06-16 | $43.58 | 720,100 |
| 2026-06-15 | $43.86 | 902,300 |
| 2026-06-12 | $44.41 | 825,400 |
| 2026-06-11 | $45.55 | 478,300 |
| 2026-06-10 | $45.09 | 380,100 |
| 2026-06-09 | $45.66 | 380,800 |
| 2026-06-08 | $44.48 | 431,300 |
| 2026-06-05 | $44.75 | 574,100 |
| 2026-06-04 | $44.70 | 460,500 |
| 2026-06-03 | $44.04 | 1,003,100 |
| 2026-06-02 | $44.07 | 711,300 |
| 2026-06-01 | $44.76 | 571,000 |
| 2026-05-29 | $46.18 | 544,800 |
| 2026-05-28 | $46.85 | 635,600 |
| 2026-05-27 | $46.64 | 711,000 |
| 2026-05-26 | $47.77 | 474,800 |
| 2026-05-22 | $48.21 | 526,800 |
| 2026-05-21 | $49.38 | 529,500 |
| 2026-05-20 | $48.69 | 606,200 |
| 2026-05-19 | $47.62 | 591,500 |
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
đ° Latest News
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
StockStory âĸ 2026-06-16T13:29:04Z
1 Cash-Heavy Stock on Our Watchlist and 2 Facing Challenges
StockStory âĸ 2026-06-05T12:56:14Z
Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate
Simply Wall St. âĸ 2026-05-24T12:11:50Z
3 Stocks Under $50 with Open Questions
StockStory âĸ 2026-05-22T21:16:55Z
3 Small-Cap Stocks That Concern Us
StockStory âĸ 2026-05-20T05:32:55Z
3 Growth Stocks We Approach with Caution
StockStory âĸ 2026-05-19T09:56:55Z
5 Revealing Analyst Questions From Supernus Pharmaceuticalsâs Q1 Earnings Call
StockStory âĸ 2026-05-15T09:40:55Z
What to Know About This Fundâs Sale of a Pharma Stock Up 56% in a Year
Motley Fool âĸ 2026-05-12T17:10:43Z
Does Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)?
Simply Wall St. âĸ 2026-05-06T17:15:02Z
Supernus Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-06T03:09:10Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $72,455,000 | $75,469,000 | $81,305,000 | $84,308,000 |
| Cost Of Revenue | $74,562,000 | $77,906,000 | $83,779,000 | $87,221,000 |
| Total Revenue | $718,952,000 | $661,817,000 | $607,521,000 | $667,238,000 |
| Operating Revenue | $718,952,000 | $661,817,000 | $607,521,000 | $667,238,000 |
| Expenses | ||||
| Interest Expense | $0 | $0 | $2,415,000 | $7,070,000 |
| Total Expenses | $755,816,000 | $586,261,000 | $594,118,000 | $621,624,000 |
| Other Income Expense | $-25,419,000 | $6,110,000 | $-18,672,000 | $510,000 |
| Net Non Operating Interest Income Expense | $13,253,000 | $16,204,000 | $8,038,000 | $14,619,000 |
| Interest Expense Non Operating | $0 | $0 | $2,415,000 | $7,070,000 |
| Operating Expense | $681,254,000 | $508,355,000 | $510,339,000 | $534,403,000 |
| Selling And Marketing Expense | $288,651,000 | $227,293,000 | $229,186,000 | $267,788,000 |
| General And Administrative Expense | $196,912,000 | $94,289,000 | $107,175,000 | $109,433,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-38,550,000 | $73,865,000 | $1,316,000 | $60,711,000 |
| Net Interest Income | $13,253,000 | $16,204,000 | $8,038,000 | $14,619,000 |
| Interest Income | $13,253,000 | $16,204,000 | $10,453,000 | $21,689,000 |
| Normalized Income | $-18,570,666 | $69,282,500 | $16,066,880 | $60,201,269 |
| Net Income From Continuing And Discontinued Operation | $-38,550,000 | $73,865,000 | $1,316,000 | $60,711,000 |
| Total Operating Income As Reported | $-62,283,000 | $81,666,000 | $-5,269,000 | $46,124,000 |
| Net Income Common Stockholders | $-38,550,000 | $73,865,000 | $1,316,000 | $60,711,000 |
| Net Income | $-38,550,000 | $73,865,000 | $1,316,000 | $60,711,000 |
| Net Income Including Noncontrolling Interests | $-38,550,000 | $73,865,000 | $1,316,000 | $60,711,000 |
| Net Income Continuous Operations | $-38,550,000 | $73,865,000 | $1,316,000 | $60,711,000 |
| Pretax Income | $-49,030,000 | $97,870,000 | $2,769,000 | $60,743,000 |
| Special Income Charges | $-25,419,000 | $6,110,000 | $-18,672,000 | $510,000 |
| Interest Income Non Operating | $13,253,000 | $16,204,000 | $10,453,000 | $21,689,000 |
| Operating Income | $-36,864,000 | $75,556,000 | $13,403,000 | $45,614,000 |
| Depreciation Amortization Depletion Income Statement | $89,456,000 | $77,977,000 | $82,385,000 | $82,630,000 |
| Depreciation And Amortization In Income Statement | $89,456,000 | $77,977,000 | $82,385,000 | $82,630,000 |
| Amortization Of Intangibles Income Statement | $89,456,000 | $77,977,000 | $82,385,000 | $82,630,000 |
| Gross Profit | $644,390,000 | $583,911,000 | $523,742,000 | $580,017,000 |
| Average Dilution Earnings | - | $0 | $0 | $3,556,000 |
| Per Share | ||||
| Diluted EPS | $-0.68 | $1.32 | $0.02 | $1.04 |
| Basic EPS | $-0.68 | $1.34 | $0.02 | $1.13 |
| Other | ||||
| Tax Effect Of Unusual Items | $-5,439,666 | $1,527,500 | $-3,921,120 | $269 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $67,952,000 | $172,174,000 | $108,715,000 | $152,846,000 |
| Total Unusual Items | $-25,419,000 | $6,110,000 | $-18,672,000 | $510,000 |
| Total Unusual Items Excluding Goodwill | $-25,419,000 | $6,110,000 | $-18,672,000 | $510,000 |
| Reconciled Depreciation | $91,563,000 | $80,414,000 | $84,859,000 | $85,543,000 |
| EBITDA (Bullshit earnings) | $42,533,000 | $178,284,000 | $90,043,000 | $153,356,000 |
| EBIT | $-49,030,000 | $97,870,000 | $5,184,000 | $67,813,000 |
| Diluted Average Shares | $56,451,136 | $55,958,537 | $55,506,828 | $61,679,800 |
| Basic Average Shares | $56,451,136 | $55,100,063 | $54,536,281 | $53,665,143 |
| Diluted NI Availto Com Stockholders | $-38,550,000 | $73,865,000 | $1,316,000 | $64,267,000 |
| Tax Provision | $-10,480,000 | $24,005,000 | $1,453,000 | $32,000 |
| Impairment Of Capital Assets | $0 | $0 | $20,189,000 | $0 |
| Restructuring And Mergern Acquisition | $25,419,000 | $-6,110,000 | $-1,517,000 | $-510,000 |
| Amortization | $89,456,000 | $77,977,000 | $82,385,000 | $82,630,000 |
| Research And Development | $106,235,000 | $108,796,000 | $91,593,000 | $74,552,000 |
| Selling General And Administration | $485,563,000 | $321,582,000 | $336,361,000 | $377,221,000 |
| Other Gand A | $196,912,000 | $94,289,000 | $107,175,000 | $109,433,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $367,376,000 | $396,802,000 | $204,608,000 | $66,722,000 |
| Total Assets | $1,452,648,000 | $1,368,073,000 | $1,277,673,000 | $1,702,508,000 |
| Total Non Current Assets | $808,466,000 | $682,003,000 | $784,560,000 | $968,357,000 |
| Other Non Current Assets | $65,246,000 | $31,527,000 | $37,505,000 | $39,806,000 |
| Non Current Deferred Assets | $38,351,000 | $0 | - | - |
| Non Current Deferred Taxes Assets | $38,351,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $694,338,000 | $638,931,000 | $716,908,000 | $819,482,000 |
| Other Intangible Assets | $569,456,000 | $521,912,000 | $599,889,000 | $702,463,000 |
| Current Assets | $644,182,000 | $686,070,000 | $493,113,000 | $734,151,000 |
| Other Current Assets | $65,325,000 | $36,088,000 | $16,676,000 | $15,779,000 |
| Inventory | $82,385,000 | $54,293,000 | $77,408,000 | $91,541,000 |
| Receivables | $187,802,000 | $142,077,000 | $144,155,000 | $165,497,000 |
| Accounts Receivable | $187,802,000 | $142,077,000 | $144,155,000 | $165,497,000 |
| Allowance For Doubtful Accounts Receivable | $-13,500,000 | $-12,300,000 | $-10,700,000 | $-13,000,000 |
| Gross Accounts Receivable | $201,302,000 | $154,377,000 | $154,855,000 | $178,497,000 |
| Cash Cash Equivalents And Short Term Investments | $308,670,000 | $453,612,000 | $254,874,000 | $461,334,000 |
| Cash And Cash Equivalents | $128,448,000 | $69,331,000 | $75,054,000 | $93,120,000 |
| Cash Equivalents | $72,077,000 | $31,501,000 | $39,097,000 | $40,939,000 |
| Cash Financial | $56,371,000 | $37,830,000 | $35,957,000 | $52,181,000 |
| Investmentin Financial Assets | - | $0 | $16,617,000 | $93,896,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $40,977,000 | $34,271,000 | $41,527,000 | $444,757,000 |
| Long Term Debt And Capital Lease Obligation | $30,365,000 | $27,382,000 | $33,196,000 | $35,998,000 |
| Current Debt And Capital Lease Obligation | $10,612,000 | $6,889,000 | $8,331,000 | $408,759,000 |
| Net Debt | - | - | - | $308,848,000 |
| Current Debt | - | - | - | $401,968,000 |
| Other Current Borrowings | - | - | - | $401,968,000 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $390,934,000 | $332,340,000 | $356,157,000 | $816,304,000 |
| Total Non Current Liabilities Net Minority Interest | $52,763,000 | $39,943,000 | $65,961,000 | $128,346,000 |
| Other Non Current Liabilities | $22,398,000 | $7,600,000 | $7,802,000 | $42,539,000 |
| Non Current Deferred Liabilities | $0 | $4,961,000 | $24,963,000 | $49,809,000 |
| Non Current Deferred Taxes Liabilities | $0 | $4,961,000 | $24,963,000 | $49,809,000 |
| Current Liabilities | $338,171,000 | $292,397,000 | $290,196,000 | $687,958,000 |
| Other Current Liabilities | $69,274,000 | $47,340,000 | $56,353,000 | $37,983,000 |
| Payables And Accrued Expenses | $228,839,000 | $216,943,000 | $204,790,000 | $224,253,000 |
| Payables | $2,677,000 | $4,587,000 | $1,964,000 | $10,543,000 |
| Accounts Payable | $2,677,000 | $4,587,000 | $1,964,000 | $10,543,000 |
| Equity | ||||
| Common Stock Equity | $1,061,714,000 | $1,035,733,000 | $921,516,000 | $886,204,000 |
| Total Equity Gross Minority Interest | $1,061,714,000 | $1,035,733,000 | $921,516,000 | $886,204,000 |
| Stockholders Equity | $1,061,714,000 | $1,035,733,000 | $921,516,000 | $886,204,000 |
| Gains Losses Not Affecting Retained Earnings | $-44,000 | $-189,000 | $-593,000 | $-3,210,000 |
| Other Equity Adjustments | $-44,000 | $-189,000 | $-593,000 | $-3,210,000 |
| Retained Earnings | $517,876,000 | $556,426,000 | $482,561,000 | $481,245,000 |
| Other | ||||
| Ordinary Shares Number | $57,457,462 | $55,743,095 | $54,723,356 | $54,253,796 |
| Share Issued | $57,457,462 | $55,743,095 | $54,723,356 | $54,253,796 |
| Tangible Book Value | $367,376,000 | $396,802,000 | $204,608,000 | $66,722,000 |
| Invested Capital | $1,061,714,000 | $1,035,733,000 | $921,516,000 | $1,288,172,000 |
| Working Capital | $306,011,000 | $393,673,000 | $202,917,000 | $46,193,000 |
| Capital Lease Obligations | $40,977,000 | $34,271,000 | $41,527,000 | $42,789,000 |
| Total Capitalization | $1,061,714,000 | $1,035,733,000 | $921,516,000 | $886,204,000 |
| Additional Paid In Capital | $543,825,000 | $479,440,000 | $439,493,000 | $408,115,000 |
| Capital Stock | $57,000 | $56,000 | $55,000 | $54,000 |
| Common Stock | $57,000 | $56,000 | $55,000 | $54,000 |
| Long Term Capital Lease Obligation | $30,365,000 | $27,382,000 | $33,196,000 | $35,998,000 |
| Current Capital Lease Obligation | $10,612,000 | $6,889,000 | $8,331,000 | $6,791,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $29,446,000 | $21,225,000 | $20,722,000 | $16,963,000 |
| Current Accrued Expenses | $226,162,000 | $212,356,000 | $202,826,000 | $213,710,000 |
| Goodwill | $124,882,000 | $117,019,000 | $117,019,000 | $117,019,000 |
| Net PPE | $10,531,000 | $11,545,000 | $13,530,000 | $15,173,000 |
| Accumulated Depreciation | $-18,264,000 | $-17,843,000 | $-15,405,000 | $-13,049,000 |
| Gross PPE | $28,795,000 | $29,388,000 | $28,935,000 | $28,222,000 |
| Leases | $13,052,000 | $14,023,000 | $14,023,000 | $14,023,000 |
| Machinery Furniture Equipment | $15,743,000 | $15,365,000 | $14,912,000 | $13,993,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $21,116,000 | $16,441,000 | $29,922,000 | $35,011,000 |
| Work In Process | $29,436,000 | $26,725,000 | $31,212,000 | $31,710,000 |
| Raw Materials | $31,833,000 | $11,127,000 | $16,274,000 | $24,820,000 |
| Other Short Term Investments | $180,222,000 | $384,281,000 | $179,820,000 | $368,214,000 |
| Investments And Advances | - | $0 | $16,617,000 | $93,896,000 |
| Treasury Shares Number | - | - | $0 | - |
| Available For Sale Securities | - | - | $16,617,000 | $93,896,000 |
| Construction In Progress | - | - | $0 | $206,000 |
| Other Properties | - | - | - | $12,127,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $45,993,000 | $171,226,000 | $110,534,000 | $116,414,000 |
| Operating Activities | ||||
| Operating Cash Flow | $47,331,000 | $171,951,000 | $111,085,000 | $116,826,000 |
| Cash Flow From Continuing Operating Activities | $47,331,000 | $171,951,000 | $111,085,000 | $116,826,000 |
| Operating Gains Losses | $439,000 | $-9,000 | - | $-14,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,338,000 | $-725,000 | $-551,000 | $-412,000 |
| Investing Cash Flow | $4,106,000 | $-189,867,000 | $268,729,000 | $-216,663,000 |
| Cash Flow From Continuing Investing Activities | $4,106,000 | $-189,867,000 | $268,729,000 | $-216,663,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $37,616,000 | $14,908,000 | $6,610,000 | $12,423,000 |
| Financing Cash Flow | $9,130,000 | $12,193,000 | $-397,880,000 | $-10,477,000 |
| Cash Flow From Continuing Financing Activities | $9,130,000 | $12,193,000 | $-397,880,000 | $-10,477,000 |
| Net Other Financing Charges | $-28,486,000 | $-2,715,000 | $-1,990,000 | $-22,900,000 |
| Net Common Stock Issuance | $37,616,000 | $14,908,000 | $6,610,000 | $12,423,000 |
| Common Stock Issuance | $37,616,000 | $14,908,000 | $6,610,000 | $12,423,000 |
| Dividends Received Cfi | - | - | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $0 | $0 | $-495,500,000 | $0 |
| Issuance Of Debt | $0 | $0 | $93,000,000 | $0 |
| Interest Paid Supplemental Data | $0 | $0 | $1,946,000 | $2,516,000 |
| Income Tax Paid Supplemental Data | $16,051,000 | $53,254,000 | $36,602,000 | $16,200,000 |
| End Cash Position | $129,898,000 | $69,331,000 | $75,054,000 | $93,120,000 |
| Beginning Cash Position | $69,331,000 | $75,054,000 | $93,120,000 | $203,434,000 |
| Changes In Cash | $60,567,000 | $-5,723,000 | $-18,066,000 | $-110,314,000 |
| Net Issuance Payments Of Debt | $0 | $0 | $-402,500,000 | $0 |
| Net Long Term Debt Issuance | $0 | $0 | $-402,500,000 | $0 |
| Long Term Debt Payments | $0 | $0 | $-495,500,000 | $0 |
| Long Term Debt Issuance | $0 | $0 | $93,000,000 | $0 |
| Net Investment Purchase And Sale | $298,537,000 | $-189,142,000 | $269,280,000 | $-216,251,000 |
| Sale Of Investment | $774,478,000 | $498,871,000 | $370,901,000 | $190,739,000 |
| Purchase Of Investment | $-475,941,000 | $-688,013,000 | $-101,621,000 | $-406,990,000 |
| Net Business Purchase And Sale | $-293,093,000 | $0 | $0 | $0 |
| Purchase Of Business | $-293,093,000 | $0 | $0 | $0 |
| Net PPE Purchase And Sale | $-1,338,000 | $-725,000 | $-551,000 | $-412,000 |
| Purchase Of PPE | $-1,338,000 | $-725,000 | $-551,000 | $-412,000 |
| Change In Working Capital | $-75,159,000 | $-2,052,000 | $-9,137,000 | $-22,143,000 |
| Change In Payables And Accrued Expense | $-32,174,000 | $-584,000 | $-33,678,000 | $-222,000 |
| Change In Accrued Expense | $-7,608,000 | $14,431,000 | $2,609,000 | $18,941,000 |
| Change In Payable | $-24,566,000 | $-15,015,000 | $-36,287,000 | $-19,163,000 |
| Change In Account Payable | $-24,566,000 | $-15,015,000 | $-36,287,000 | $-19,163,000 |
| Change In Prepaid Assets | $-13,179,000 | $-19,352,000 | $-334,000 | $12,303,000 |
| Change In Inventory | $-7,502,000 | $15,806,000 | $6,110,000 | $-17,858,000 |
| Change In Receivables | $-22,304,000 | $2,078,000 | $18,765,000 | $-16,366,000 |
| Changes In Account Receivables | $-22,304,000 | $2,078,000 | $18,765,000 | $-16,366,000 |
| Other Non Cash Items | $30,384,000 | $1,415,000 | $4,912,000 | $-12,190,000 |
| Stock Based Compensation | $33,051,000 | $27,755,000 | $26,759,000 | $17,568,000 |
| Asset Impairment Charge | $1,926,000 | $8,876,000 | $28,212,000 | $10,442,000 |
| Amortization Of Securities | $-1,529,000 | $1,823,000 | $-122,000 | $3,233,000 |
| Deferred Tax | $5,206,000 | $-20,136,000 | $-25,714,000 | $-26,324,000 |
| Deferred Income Tax | $5,206,000 | $-20,136,000 | $-25,714,000 | $-26,324,000 |
| Depreciation Amortization Depletion | $91,563,000 | $80,414,000 | $84,859,000 | $85,543,000 |
| Depreciation And Amortization | $91,563,000 | $80,414,000 | $84,859,000 | $85,543,000 |
| Gain Loss On Investment Securities | $439,000 | $-9,000 | - | $-14,000 |
| Net Income From Continuing Operations | $-38,550,000 | $73,865,000 | $1,316,000 | $60,711,000 |
| Net Short Term Debt Issuance | - | - | $-402,500,000 | $0 |
| Short Term Debt Payments | - | - | $-402,500,000 | $0 |
| Short Term Debt Issuance | - | - | $93,000,000 | $0 |
| Change In Other Current Liabilities | - | - | $0 | $-2,100,000 |
Fetched: 2026-06-17